Clinical trials: sponsored by Hoffmann-La Roche
Ovarian Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian…
- Trial name
- NCT01863693
- Where
- 30 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT01174563
- Testing
- erlotinib [Tarceva]
- Where
- 16 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01010061
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01998880
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT02053610
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel…
- Trial name
- SAPPHIRE (NCT02019277)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 13 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
This open-label, single arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as first-line therapy in participants with stage IV or recurrent non-small cell lung cancer who harbour epidermal growth factor…
- Trial name
- NCT01310036
- Testing
- Erlotinib
- Where
- 22 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis.
- Trial name
- NCT01705730
- Testing
- tocilizumab
- Where
- 17 sites in Belgium
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Infections
A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
This observational study will compare spermatogenesis in male adult renal transplant recipients receiving valganciclovir versus untreated matched controls.
- Trial name
- NCT01663740
- Testing
- Valganciclovir
- Where
- 19 sites in United States, Mexico
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Hepatic Impairment
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
This is a multicenter, non-randomized, single-dose, open-label study conducted in male and surgically sterile or post-menopausal female participants with stable chronic hepatic impairment and in healthy participants matched by…
- Trial name
- NCT02621047
- Testing
- Alectinib
- Where
- 2 sites in Czechia, Slovakia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with…
- Trial name
- NCT01872689
- Testing
- Lebrikizumab, Pirfenidone
- Where
- 112 sites in United States, Australia and 11 more
- Volunteers
- 505 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
This study will evaluate the efficacy and safety of subcutaneous (SC) epoetin beta in anemic participants with breast cancer undergoing chemotherapy.
- Trial name
- NCT02761642
- Testing
- Epoetin Beta
- Where
- 27 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
This prospective, multicenter, observational study will investigate the effectiveness and safety of bevacizumab in routine clinical practice in participants with metastatic CRC.
- Trial name
- AVACONT (NCT02305615)
- Testing
- Bevacizumab, Chemotherapy
- Where
- 22 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
- Trial name
- NCT03330990
- Testing
- Entrectinib, Midazolam Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment.
- Trial name
- NCT01871805
- Testing
- Alectinib
- Where
- 42 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic…
- Trial name
- NCT01026142
- Testing
- Capecitabine, Pertuzumab, Trastuzumab
- Where
- 190 sites in Argentina, Austria and 21 more
- Volunteers
- 452 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
This randomized, multicenter, open-label study will evaluate two different doses of pertuzumab in combination with Herceptin (trastuzumab) and chemotherapy in the first-line treatment of participants with metastatic HER2-positive…
- Trial name
- JOSHUA (NCT01461057)
- Testing
- Capecitabine, Cisplatin, Pertuzumab
- Where
- 24 sites in Belgium, Czechia and 6 more
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Sjogren's Syndrome
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants…
- Trial name
- NCT02701985
- Testing
- RO5459072
- Where
- 31 sites in United States, France and 4 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Acute Myocardial Infarctus
Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
Objectives of the phase 2 prospective, multicenter, randomized, double-blind, placebo-controlled study is to assess safety and efficacy of TRO40303 administered just before balloon inflation during percutaneous coronary…
- Trial name
- NCT01374321
- Testing
- TRO40303
- Where
- 11 sites in Denmark, France and 2 more
- Volunteers
- 168 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.